

### **3 Ways and 4 Ways Bioequivalent Studies**

As agreed upon in 'Mesyuarat Jawatankuasa Kerja Bioekuivalens Kebangsaan 1/2009 – 19 Ogos 2009':

'3 ways' and '4 ways' study design can be allowed as follows:

|   |  |
|---|--|
| <p><u>Scenario A</u></p> <p>Study which involved the same sponsor</p> <p>i) Reference Tablet 500mg vs</p> <ul style="list-style-type: none"><li>- Test A 250mg Tablet &amp; Test A 500mg Tablet</li></ul> <p>ii) Reference Tablet 500mg vs</p> <ul style="list-style-type: none"><li>- Test A 250mg Tablet &amp; Test A 250mg/5ml Suspension</li></ul> <p>ii) Test A 250mg Tablet vs</p> <ul style="list-style-type: none"><li>- Reference Tablet 250mg from Austria &amp; Reference Tablet 250mg from UK</li></ul> | <p>Scenario A is allowed since it is a standard design . However, it is only restricted up to '4 ways' only.</p>   |
| <p><u>Scenario B</u></p> <p>Study which involved more than 1 sponsor with the same comparator</p> <p>i) Reference Tablet 250mg vs</p> <ul style="list-style-type: none"><li>- Test 250mg Tablet from manufacturer A &amp; Test 250mg Tablet from manufacturer B</li></ul>   | <p>Scenario B is allowed with the following conditions:</p> <ul style="list-style-type: none"><li>i) Applicant need to declare that the study is using '3 ways' or '4 ways' design.</li><li>ii) Report of BE study must include information for all products involved (3 ways – 3 products, 4 ways – 4 products)</li></ul> |